Phase II clinical trial of pembrolizumab efficacy and safety in advanced adrenocortical carcinoma | Journal for ImmunoTherapy of Cancer
PDF) New clinical trial designs in the era of Precision Medicine
Studiehistorikk - Phase1
Targeting FGFR inhibition in cholangiocarcinoma - ScienceDirect
Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): a multicentre, open-label, phase 2a, multiple basket study - The Lancet Oncology
Caris Life Sciences Partners with Debiopharm International SA to Develop Companion Diagnostic for Detection of Rare FGFR Fusions
PDF) 560P Safety and efficacy of Debio 1143, an antagonist of inhibitor of apoptosis proteins (IAPs), in combination with nivolumab in a phase Ib/II trial in patients (pts) failing prior PD-1/PD-L1 treatment
Frontiers | Precision Medicine Targeting FGFR2 Genomic Alterations in Advanced Cholangiocarcinoma: Current State and Future Perspectives
Targeted therapies: Expanding the role of FGFR3 inhibition in urothelial carcinoma - ScienceDirect
2020 Scientific Report
Frontiers | Revisiting targeted therapy and immunotherapy for advanced cholangiocarcinoma
Debio 1347-201 – Phase II basket trial in solid tumors harboring a fusion of FGFR1-3
Cancers | Free Full-Text | Targeted Therapies in Advanced Biliary Tract Cancer: An Evolving Paradigm
Radiotherapy as a tool to elicit clinically actionable signalling pathways in cancer | Nature Reviews Clinical Oncology
Open-label, non-randomized, exploratory pre-operative window-of-opportunity trial to investigate the pharmacokinetics and pharma
Pharmaceuticals | Free Full-Text | TRK Inhibitors: Tissue-Agnostic Anti-Cancer Drugs
Phase II clinical trial of pembrolizumab efficacy and safety in advanced adrenocortical carcinoma | Journal for ImmunoTherapy of Cancer
Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): a multicentre, open-label, phase 2a, multiple basket study - The Lancet Oncology
Cancers | Free Full-Text | Novel Pharmacological Options in the Treatment of Cholangiocarcinoma: Mechanisms of Resistance
FGFR inhibitors in cholangiocarcinoma: what's now and what's next? - Anna Saborowski, Ulrich Lehmann, Arndt Vogel, 2020
Cureus | Current Targeted Therapy Options in the Treatment of Cholangiocarcinoma: A Literature Review | Article
Table of Contents page: Annals of Oncology
First-in-human Phase I “Basket” Study of Debio 1347 (CH5183284), a Novel FGFR Inhibitor in Patients with FGFR Genomically
Cureus | Current Targeted Therapy Options in the Treatment of Cholangiocarcinoma: A Literature Review | Article
Open-label, non-randomized, exploratory pre-operative window-of-opportunity trial to investigate the pharmacokinetics and pharma
